US 11,673,963 B2
CRTAM antibodies and methods of treating cancer
Arnima Bisht, San Jose, CA (US); Rachel L. Dusek, San Jose, CA (US); Haining Huang, San Jose, CA (US); Chuck Hannum, San Jose, CA (US); James Edward Ackroyd, Abingdon (GB); and Livija Deban, Abingdon (GB)
Assigned to Oxford BioTherapeutics Ltd, Abingdon (GB)
Appl. No. 16/760,180
Filed by Oxford BioTherapeutics Ltd, Abingdon (GB)
PCT Filed Nov. 1, 2018, PCT No. PCT/GB2018/053165
§ 371(c)(1), (2) Date Apr. 29, 2020,
PCT Pub. No. WO2019/086878, PCT Pub. Date May 9, 2019.
Claims priority of provisional application 62/697,145, filed on Jul. 12, 2018.
Claims priority of provisional application 62/580,667, filed on Nov. 2, 2017.
Prior Publication US 2020/0262927 A1, Aug. 20, 2020
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
OG exemplary drawing
 
1. An antibody, or an antigen-binding fragment thereof, that binds to CRTAM, said antibody, or antigen-binding fragment thereof, comprising:
i) the 3 heavy chain CDRs of SEQ ID NO:1 and the 3 light chain CDRs of SEQ ID NO: 2 or
ii) the 3 heavy chain CDRs of SEQ ID NO:13 and the 3 light chain CDRs of SEQ ID NO: 14;
wherein the CDRs are defined by the Kabat or by the Chothia numbering system.